云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01952 云顶新耀

休市中 12-19 16:08:06

49.020

+0.920

+1.91%

最高49.660	最低48.300	成交量392.50万
今开48.480	昨收48.100	日振幅2.83%
总市值173.53亿	流通市值173.53亿	总股本3.54亿
成交额1.92亿	换手率1.11%	流通股本3.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01952","market":"HK","secType":"STK","nameCN":"云顶新耀","latestPrice":49.02,"timestamp":1766131686005,"preClose":48.1,"halted":0,"volume":3925000,"delay":0,"floatShares":354000000,"shares":354000000,"eps":-3.591082298243703,"marketStatus":"休市中","change":0.92,"latestTime":"12-19 16:08:06","open":48.48,"high":49.66,"low":48.3,"amount":192208985,"amplitude":0.028274,"askPrice":49.02,"askSize":93500,"bidPrice":49,"bidSize":13000,"shortable":3,"etf":0,"ttmEps":-2.255311070236326,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":7,"adr":0,"listingDate":1602172800000,"exchange":"SEHK","adjPreClose":48.1,"openAndCloseTimeList":[[1766107800000,1766116800000],[1766120400000,1766131200000]],"volumeRatio":0.7163507338047108,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01952","defaultTab":"news","newsList":[{"id":"2592974682","title":"云顶新耀2030战略落地：创新与全球化实力获认可","url":"https://stock-news.laohu8.com/highlight/detail?id=2592974682","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592974682?lang=zh_cn&edition=full","pubTime":"2025-12-18 17:52","pubTimestamp":1766051570,"startTime":"0","endTime":"0","summary":"日前，由数字化智库型财经媒体领跑者《21世纪经济报道》与21世纪新健康研究院发起2025年第九届21世纪大健康产业竞争力研究“阳光”案例正式揭晓。作为大健康产业领域极具权威性的年度评选成果，本次公布的案例集中展现了当下产业内的创新活力、技术突破与实践典范，为行业高质量发展树立了鲜明标杆。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512183595560991.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512183595560991.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01952","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2592838922","title":"体内CAR-T赛道白热化：盘点国内19家核心企业管线全景图","url":"https://stock-news.laohu8.com/highlight/detail?id=2592838922","media":"求实药社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592838922?lang=zh_cn&edition=full","pubTime":"2025-12-18 12:02","pubTimestamp":1766030559,"startTime":"0","endTime":"0","summary":"跨国药企重磅加注，国内Biotech加速推进，体内CAR-T已成细胞治疗领域的热门赛道。这项颠覆性技术旨在解决传统CAR-T高成本、长周期的痛点，并进一步拓展血液瘤、实体瘤及自免疾病适应症。纵观国内研发格局，体内CAR-T正呈现出“技术路线多元化”与“临床验证加速化”的双重特征。从进展来看，IIT已成为当前验证体内CAR-T安全性与有效性的主战场。2025年3月完成首例患者给药，进入临床阶段，是国内较早进入体内CAR临床阶段的企业之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218134128a459f8ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218134128a459f8ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01952","BK1161","LEGN","BK1583"],"gpt_icon":0},{"id":"2592924098","title":"云顶新耀，拿下六个原研！","url":"https://stock-news.laohu8.com/highlight/detail?id=2592924098","media":"药通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592924098?lang=zh_cn&edition=full","pubTime":"2025-12-17 17:32","pubTimestamp":1765963946,"startTime":"0","endTime":"0","summary":"12月11日，云顶新耀宣布与海森生物签署两项战略合作协议，其一是6款成熟产品的商业化服务协议；其二是正在研发的PCSK9抑制剂“莱达西贝普”后续大中华区的开发、注册、商业化独家许可协议。经查，海森生物和云顶新耀背后均是康桥资本操控，此次合作可理解为左右手互助。因此云顶新耀无需显著增加成本，利用现有渠道就能创造增量。就在今日，云顶新耀宣布莱达西贝普已获FDA批准上市，EMA正处于审批中，计划2026年上半年于大中华区递交BLA。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217175309a6ad7afa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217175309a6ad7afa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01952","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2592924043","title":"每日卖空追踪 | 云顶新耀 12月17日卖空量成交16.7万股，卖空比例为3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592924043","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592924043?lang=zh_cn&edition=full","pubTime":"2025-12-17 16:30","pubTimestamp":1765960225,"startTime":"0","endTime":"0","summary":"云顶新耀北京时间12月17日，涨6.79%，卖空量成交16.7万股，较上一交易日减少65.24%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217163402a4561287&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217163402a4561287&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","01952","BK1161","BK1574"],"gpt_icon":0},{"id":"2592690359","title":"云顶新耀(01952.HK)涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592690359","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592690359?lang=zh_cn&edition=full","pubTime":"2025-12-17 14:33","pubTimestamp":1765953197,"startTime":"0","endTime":"0","summary":"每经AI快讯，云顶新耀(01952.HK)涨超3%，截至发稿涨3.46%，报48.44港元，成交额1.31亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512173594155348.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512173594155348.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","01952","BK1161","BK1574"],"gpt_icon":0},{"id":"2592696966","title":"港股异动 | 云顶新耀(01952)涨超3% 乐瑞泊®获FDA批准 预计明年上半年于大中华区递交BLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2592696966","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592696966?lang=zh_cn&edition=full","pubTime":"2025-12-17 14:17","pubTimestamp":1765952274,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀涨超3%，截至发稿，涨3.46%，报48.44港元，成交额1.31亿港元。2025年12月，云顶新耀与海森生物签署授权许可协议，获得了在大中华区开展乐瑞泊的后续临床开发、注册和商业化的独家许可。乐瑞泊是一款新型小分子蛋白结合的第三代PCSK9抑制剂，旨在帮助患者达成并长期维持其LDL-C控制目标。作为首个PCSK9抑制剂融合蛋白，乐瑞泊免疫原性低，安全性出众。以上特点使乐瑞泊成为已获批的PCSK9抑制剂的独特替代方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382497.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 云顶新耀(01952)涨超3% 乐瑞泊®获FDA批准 预计明年上半年于大中华区递交BLA","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01952","BK1583","BK1161"],"gpt_icon":0},{"id":"2592993687","title":"云顶新耀12月16日遭主力抛售233.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592993687","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592993687?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:16","pubTimestamp":1765872962,"startTime":"0","endTime":"0","summary":"12月16日, 云顶新耀股价跌0.13%，报收46.82元，成交金额1.5亿元，换手率0.93%，振幅2.86%，量比0.77。云顶新耀今日主力资金净流出233.8万元，上一交易日主力净流出178.2万元。该股近5个交易日上涨8.55%，主力资金累计净流入614.7万元；近20日主力资金累计净流入1233.7万元，其中净流入天数为8日。该股主力净额占比0.01%，港股市场排名2383/2689。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216162310a45191d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216162310a45191d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01952","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2591983074","title":"围绕2030年发展，多家国内外药企发布相关战略及愿景！","url":"https://stock-news.laohu8.com/highlight/detail?id=2591983074","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591983074?lang=zh_cn&edition=full","pubTime":"2025-12-16 13:11","pubTimestamp":1765861889,"startTime":"0","endTime":"0","summary":"2025年，有多家国内外药企围绕2030年发展，发布了相关战略或明确核心愿景，涵盖创新研发、商业化目标、全球化布局等多个维度。云顶新耀近日，云顶新耀发布2030年发展战略，系统规划了未来五年的发展路径。复星医药复星医药在2030年前设定了多项发展目标，主要聚焦于创新药研发、国际化战略、市场地位提升及业务结构优化等方面。在去年其提出过“中国2030战略”，当前该战略首期答卷已在第八届进博会上披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216131228a450e749&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216131228a450e749&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01952","BK1161","BK1574","PFE","06978","BK1583"],"gpt_icon":0},{"id":"2591677725","title":"云顶新耀的进阶时刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2591677725","media":"氨基观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591677725?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:51","pubTimestamp":1765803060,"startTime":"0","endTime":"0","summary":"在18A阵营中，云顶新耀是为数不多已经证实其具备跨越商业化“死亡之谷”的企业。然而，正如公司董事会荣誉主席傅唯在电话会上所强调，今天的云顶新耀，正处于八年来最具战斗力、最有实力、资源最充沛的阶段。这正是云顶新耀突围的机遇所在。而云顶新耀前瞻的商业化布局，更为这款产品的市场突围增添了重要砝码。首先，这笔合作将为云顶新耀带来可观的现金流补充。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215213801a44e57f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215213801a44e57f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1574","BK1161","01952"],"gpt_icon":0},{"id":"2591167774","title":"每日卖空追踪 | 云顶新耀 12月15日卖空量成交18.6万股，卖空比例为2.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591167774","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591167774?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:30","pubTimestamp":1765787425,"startTime":"0","endTime":"0","summary":"云顶新耀北京时间12月15日，涨4.55%，卖空量成交18.6万股，较上一交易日减少64.44%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163346a6a456c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163346a6a456c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01952","BK1583","BK1574","BK1161"],"gpt_icon":0},{"id":"2591692390","title":"云顶新耀发布2030战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2591692390","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591692390?lang=zh_cn&edition=full","pubTime":"2025-12-15 11:51","pubTimestamp":1765770668,"startTime":"0","endTime":"0","summary":"南方财经12月15日电，记者获悉，云顶新耀2030战略以“BD合作+自研”双轮驱动为核心，明确通过引进创新资产与自主研发并行推进，实现商业化创造确定性价值、自研创造成长性价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512153591549523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01952","BK1161","BK1583","BK1574"],"gpt_icon":0},{"id":"2591695868","title":"港股异动 | 云顶新耀涨超7%，董事及主要股东增持超过3800万港元股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2591695868","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591695868?lang=zh_cn&edition=full","pubTime":"2025-12-15 09:57","pubTimestamp":1765763845,"startTime":"0","endTime":"0","summary":"12月15日，董事及主要股东增持，$云顶新耀(01952)$盘初涨超7%。消息面上，云顶新耀发布公告称，非执行董事、董事会荣誉主席兼本公司主要股东傅唯先生，执行董事兼董事会主席吴以芳先生，执行董事兼本公司首席执行官罗永庆先生，以及执行董事、总裁兼本公司首席财务官何颖先生分别于市场购入33.9万股、27.7万股、13.25万股及9.82万股公司普通股，总代价超过3800万港元，平均价格约为每股股份45.01港元。此外，作为公司主要股东的康桥资本亦在公告中明确表示，在视市场状况及在适用法律及监管的规限下，进一步承诺计划于未来三至六个月内将其持股比例累计增加不多于1%。","market":"sh","thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381338.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01952","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2591836660","title":"云顶新耀(01952)获董事及主要股东增持超过3800万港元股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2591836660","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591836660?lang=zh_cn&edition=full","pubTime":"2025-12-15 07:21","pubTimestamp":1765754512,"startTime":"0","endTime":"0","summary":"公司获告知，在视市场状况及在适用法律及监管的规限下，康桥资本已进一步承诺其计划于未来三至六个月内将其持股比例累计增加不多于1%。董事会相信，董事透过场内收购股份进行的自愿购股，以及康桥资本作出的承诺，均彰显了对公司未来前景及长远发展的坚定信心。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01952","BK1583","BK1574"],"gpt_icon":0},{"id":"1157646281","title":"云顶新耀 - 主席及其他高管于12月12日增持公司股份，总金额超过3800万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1157646281","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157646281?lang=zh_cn&edition=full","pubTime":"2025-12-15 07:04","pubTimestamp":1765753482,"startTime":"0","endTime":"0","summary":"云顶新耀 - 主席及其他高管于12月12日增持公司股份，总金额超过3800万港元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2591633353","title":"耐赋康之后，谁接棒？云顶新耀为千亿市值铺路","url":"https://stock-news.laohu8.com/highlight/detail?id=2591633353","media":"药创新","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591633353?lang=zh_cn&edition=full","pubTime":"2025-12-12 18:11","pubTimestamp":1765534287,"startTime":"0","endTime":"0","summary":"10月21日，云顶新耀在公司发展战略交流会上，明确提出要向千亿市值的目标发起冲击。此次合作是云顶新耀拓展新治疗领域的关键落子，也为其冲刺千亿市值的目标按下了“加速键”。这种“长坡厚雪”的赛道特性，对于云顶新耀而言，莱达西贝普的引进不仅是新增一款心血管产品，更对于其冲击千亿市值目标具有重要的战略价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212202120a69bfab2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212202120a69bfab2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1583","BK1574","01952"],"gpt_icon":0},{"id":"2591382633","title":"每日卖空追踪 | 云顶新耀 12月12日卖空量成交28.35万股，卖空比例为5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591382633","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591382633?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:30","pubTimestamp":1765528224,"startTime":"0","endTime":"0","summary":"云顶新耀北京时间12月12日，涨2.47%，卖空量成交28.35万股，较上一交易日增加134.3%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212165411a4446b75&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212165411a4446b75&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1583","01952","BK1161"],"gpt_icon":0},{"id":"2591633336","title":"云顶新耀12月12日主力净流入1622.3万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2591633336","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591633336?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:16","pubTimestamp":1765527360,"startTime":"0","endTime":"0","summary":"12月12日, 云顶新耀股价涨2.47%，报收44.84元，成交金额2.5亿元，换手率1.59%，振幅5.80%，量比2.35。云顶新耀今日主力资金净流入1622.3万元，上一交易日主力净流出123.4万元。该股近5个交易日下跌4.45%，主力资金累计净流入1296.9万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入1323.4万元，其中净流入天数为8日。该股主力净额占比0.11%，港股市场排名93/2691。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212162851a69b7683&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212162851a69b7683&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","BK1574","01952"],"gpt_icon":0},{"id":"2590573850","title":"港股云顶新耀午后涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590573850","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590573850?lang=zh_cn&edition=full","pubTime":"2025-12-12 14:40","pubTimestamp":1765521658,"startTime":"0","endTime":"0","summary":"每经AI快讯，云顶新耀(01952.HK)午后涨超4%，截至发稿，涨4.65%，报45.8港元，成交额1.72亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512123590082781.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512123590082781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1583","BK1161","01952"],"gpt_icon":0},{"id":"2591633386","title":"云顶新耀 24 亿元引进！第三代 PCSK9 抑制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2591633386","media":"药研界面","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591633386?lang=zh_cn&edition=full","pubTime":"2025-12-12 13:04","pubTimestamp":1765515879,"startTime":"0","endTime":"0","summary":"莱达西贝普由美国私人公司 LIB Therapeutics 研发，是一款新型小分子蛋白结合的第三代 PCSK9 抑制剂，用于降低成人高胆固醇血症患者的低密度脂蛋白胆固醇水平。目前，该产品已分别向 FDA 和 EMA 递交上市申请，并预计将在 2026 年上半年于大中华区递交生物制品上市申请，最快有望于 2027 年获得批准并上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212132631a443ff2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212132631a443ff2d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1583","BK1161","01952"],"gpt_icon":0},{"id":"2590475925","title":"港股早知道 | 国际银价续创新高；汇丰：预计美联储明后两年不会降息；云顶新耀与海森生物达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2590475925","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590475925?lang=zh_cn&edition=full","pubTime":"2025-12-12 09:00","pubTimestamp":1765501238,"startTime":"0","endTime":"0","summary":"此前美联储政策制定者以分化的表决结果将利率下调了25个基点。云顶新耀宣布与海森生物达成战略合作，发挥商业化平台的优势与布局2025年12月11日，港股创新药企云顶新耀宣布，其全资附属公司云顶新耀医药科技有限公司已与海森生物医药有限公司签署两项战略合作协议：商业化服务协议以及授权许可协议。本次增持后，朱江明及傅利泉与所属的单一最大股东集团合共持有公司2.09亿股H股及1.29亿股内资股，占公司已发行总股数的23.75%。","market":"hk","thumbnail":"https://static.tigerbbs.com/38508134c6853c521e764dc952e7334a","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/38508134c6853c521e764dc952e7334a"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380662.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","BK1147","IE00BZ08YT58.USD","01952","06099","09863","BK1515","BK1191","BK1183","BK1521","BK1574","IE00BZ08YS42.EUR","09969","HK0000165453.HKD","IE00BZ08YR35.GBP","01177","02670","BK1564","BK1583","BK1119","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.everestmedicines.com","stockEarnings":[{"period":"1week","weight":0.0932},{"period":"1month","weight":0.0962},{"period":"3month","weight":-0.1519},{"period":"6month","weight":-0.0006},{"period":"1year","weight":0.0463},{"period":"ytd","weight":0.0128}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0054},{"period":"3month","weight":-0.0322},{"period":"6month","weight":0.0918},{"period":"1year","weight":0.3006},{"period":"ytd","weight":0.2807}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"云顶新耀有限公司是一家主要从事创新药及疫苗研发、临床开发、制造及商业化的生物制药公司。该公司已建立跨肾病、抗感染及自身免疫性疾病的产品管线。该公司的产品管线包括用于肾病治疗领域的耐赋康（TARPEYO）、用于治疗包括临床常见的革兰氏阴性菌、革兰氏阳性菌、厌氧菌等多重耐药菌的感染的依嘉（依拉环素）等产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.001711},{"month":2,"riseRate":0.4,"avgChangeRate":0.052947},{"month":3,"riseRate":0.4,"avgChangeRate":0.004093},{"month":4,"riseRate":0.2,"avgChangeRate":-0.095155},{"month":5,"riseRate":0.4,"avgChangeRate":-0.02945},{"month":6,"riseRate":0.8,"avgChangeRate":0.307082},{"month":7,"riseRate":0.2,"avgChangeRate":-0.114966},{"month":8,"riseRate":0.2,"avgChangeRate":-0.112869},{"month":9,"riseRate":0.6,"avgChangeRate":0.046163},{"month":10,"riseRate":0.4,"avgChangeRate":-0.024036},{"month":11,"riseRate":0.5,"avgChangeRate":0.086142},{"month":12,"riseRate":0.833333,"avgChangeRate":0.174391}],"exchange":"SEHK","name":"云顶新耀","nameEN":"EVEREST MED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供云顶新耀(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"云顶新耀,01952,云顶新耀股票,云顶新耀股票老虎,云顶新耀股票老虎国际,云顶新耀行情,云顶新耀股票行情,云顶新耀股价,云顶新耀股市,云顶新耀股票价格,云顶新耀股票交易,云顶新耀股票购买,云顶新耀股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供云顶新耀(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}